Taipei, Taiwan
Taipei, Taiwan

Time filter

Source Type

Thymus cancer is an uncommon tumor, best known for its association with the neuromuscular disorder myasthenia gravis and is found in 20% of patients with myasthenia gravis. It is a rare type of cancer which accounts for only 1 % of total cancers. The tumor occurs at the rate of only 1.5 cases in million people each year in the United States. Once diagnosed, thymus cancer can be removed surgically. The report for Global thymus cancer market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. • Amgen Inc • Astellas Pharma Inc • Astrazeneca • Bristol-Myers Squibb • Celgene Corporation • Cellceutix Corporation • Eli Lilly and company • Johnson & Johnson services Inc • Merck & Co. Inc. • Novartis AG • Onxeo SA • Pfizer Inc • Sumitomo Dainippon Pharma Co. Ltd. • Taiwan Liposome Company Ltd. • Takeda pharmaceutical company • Tiziana Life Sciences Plc. Market Highlights: Thymus cancer is a tumor formed on the outer surface originating from the epithelial cells of the thymus. Thymus is a small organ located in the upper chest under the breast bone and makes specific type of white blood cells which help the body fight infection. There are no prominent causes or risk factors for thymus cancer. In the rare cases of a malignant tumor, chemotherapy may also be used. The market for thymus cancer is showing a limited growth. Taste the market data and market information presented through more than 50 market data tables and figures spread in 90 numbers of pages of the project report. Avail the in-depth table of content TOC & market synopsis on “Global Thymus Cancer Market Research Report- Forecast To 2024” • To provide detailed analysis of the market structure along with forecast for the next 8 years of the various segments and sub-segments of the thymus cancer market • To provide insights about factors affecting the market growth • To analyze the thymus cancer market based on various factors- price analysis, supply chain analysis, porters five force analysis etc. • To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa. • To provide country level analysis of the market with respect to the current market size and future prospective • To provide country level analysis of the market for segments by type, by treatment, care centers and its sub-segments. • To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global thymus cancer market. • Thymus cancer drug manufacturers • Thymus cancer drug suppliers • Research and Development (R&D) Companies • Government Research Laboratories • Independent Research Laboratories • Government and Independent Regulatory Authorities • Market Research and Consulting Service Providers • Medical Research Laboratories • Academic Medical Institutes and Universities Global thymus cancer market has been segmented on the basis of types which comprises of type A, type AB, type B1, type B2, type B3 and thymic carcinoma (type C). On the basis of treatment, which consist of surgery, radiotherapy, chemotherapy and others. On the basis of care centers, market is segmented into hospitals, clinics, diagnostic centers, research laboratories and others. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. Global Medical Holography Information, by types (Reflection holography, Transmission holography, Hybrid Holography and others), by applications (Endoscopy, Medical Tomography, Ophthalmology, Dentistry, Otology, Orthopedics, X-Rays and others) By end users (Research Laboratories, Medical Academic Institutes, Hospitals and Clinics, Life Science Companies and others) - Forecast to 2027 About Market Research Future: At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions. For more information, please visit https://www.marketresearchfuture.com/reports/thymus-cancer-market


Patent
Taiwan Liposome Company and TLC Biopharmaceuticals Inc. | Date: 2014-04-09

The invention provides a sustained release composition for intravitreal injection to the eye of a subject in need thereof. The sustained release composition contains an effective amount of a therapeutic agent in association with a nanosphere. The nanosphere contains a particle that comprises a particle-forming component capable of forming a vesicle, and an agent-carrying component capable of forming a complex with the therapeutic agent via electrostatic charge-charge interaction or hydrophobic-hydrophobic interaction. The particle-forming component has at least one head group moiety selected from a hydrophobic head group moiety, a polar head group moiety and a combination thereof. The agent-carrying component is a chemical entity that contains one or more negatively or positively charged groups.


Patent
Taiwan Liposome Co. and Tlc Biopharmaceuticals Inc. | Date: 2013-07-05

Disclosed herein are methods of treating arthritis, comprising administering a sustained release composition comprising liposomes comprising one or more phospholipids, cholesterol, and a therapeutic agent. The sustained release composition can be administered intraarticularly.


Patent
Taiwan Liposome Company and TLC Biopharmaceuticals Inc. | Date: 2012-11-02

The present invention provides a pharmaceutical composition comprising at least one hydrophobic camptothecin derivative or a pharmaceutically acceptable salt of said derivative and a polyethylene glycol (PEG) conjugated phospholipid. Also provided is a method to inhibit cancer cells in a subject in need thereof by administering the pharmaceutical composition of the present invention.


Patent
TLC Biopharmaceuticals Inc. and Taiwan Liposome Company | Date: 2014-03-07

The invention provides a sustained release composition for intravitreal injection to the eye of a subject in need thereof. The sustained release composition contains an effective amount of a therapeutic agent in association with a nanosphere. The nanosphere contains a particle that comprises a particle-forming component capable of forming a vesicle, and an agent-carrying component capable of forming a complex with the therapeutic agent via electrostatic charge-charge interaction or hydrophobic-hydrophobic interaction. The particle-forming component has at least one head group moiety selected from a hydrophobic head group moiety, a polar head group moiety and a combination thereof. The agent-carrying component is a chemical entity that contains one or more negatively or positively charged groups.


Patent
Taiwan Liposome Company and Tlc Biopharmaceuticals Inc. | Date: 2013-02-08

The present invention relates to pharmaceutical compositions comprising a combination of a lipid cake mixture comprising one or more phospholipids, with or without cholesterol, and a steroid solution comprising an ocular steroid, derivative thereof a pharmaceutically acceptable salt thereof or a prodrug thereof, wherein the total amount of the phospholipid in the said composition is about 0.1 umol to less than about 2.5 umol per 50 ul of pharmaceutical composition and the side effects of the ocular steroid are reduced. The pharmaceutical composition is preferably administered by ocular route to treat ophthalmic diseases.


Patent
Taiwan Liposome Company and Tlc Biopharmaceuticals Inc. | Date: 2014-03-15

The present invention relates to a pharmaceutical composition comprising at least one liposome, at least one polyvalent counterion donor or a pharmaceutically acceptable salt thereof, at least one monovalent counterion donor or a pharmaceutically acceptable salt thereof, and an amphipathic therapeutic agent. The present invention also relates to methods of inhibiting cancer cell growth, comprising administering the pharmaceutical composition described herein.


Patent
Taiwan Liposome Company and TLC Biopharmaceuticals Inc. | Date: 2013-11-12

The present invention is directed to a method of inhibiting cancer cell growth, comprising administering a pharmaceutical composition to a subject in need thereof. The pharmaceutical composition comprises at least one camptothecin derivative or a pharmaceutically acceptable salt thereof; and at least one PEG phospholipid, and provides a sustained release of topotecan as an active ingredient.


Patent
Taiwan Liposome Co. | Date: 2014-12-17

An ophthalmic drug delivery system that contains phospholipid and cholesterol for prolonging drug lifetime in the eyes.


Patent
TAIWAN LIPOSOME Co. and Tlc Biopharmaceuticals Inc. | Date: 2014-12-16

An ophthalmic drug delivery system that contains phospholipid and cholesterol for prolonging drug lifetime in the eyes.

Loading Taiwan Liposome Company collaborators
Loading Taiwan Liposome Company collaborators